• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Sonendo Inc.

    2/26/25 4:16:48 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care
    Get the next $SONX alert in real time by email
    S-8 POS 1 form_s-8_pos_333-260680.htm S-8 POS S-8 POS

     

    As filed with the Securities and Exchange Commission on February 26, 2025

    Registration No. 333-260680
    Registration No. 333-263803
    Registration No. 333-270367
    Registration No. 333-270368
    Registration No. 333-277817
    Registration No.
    333-279931

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-260680

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-263803

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-270367

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-270368

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-277817

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-279931

     

    UNDER

    THE SECURITIES ACT OF 1933

     

    Sonendo, Inc.

    (Exact name of registrant as specified in its charter)

    Delaware

    20-5041718

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification Number)

    26061 Merit Circle, Suite 102

    Laguna Hills, CA

    92653

    (Address of Principal Executive Offices)

    (Zip Code)

     

     

    2007 Stock Plan
    2017 Stock Incentive Plan
    2021 Incentive Award Plan
    2021 Employee Stock Purchase Plan
    2023 Employment Inducement Incentive Award Plan

    (Full Title of the Plan)

     

     

    Bjarne Bergheim

     


     

    President and Chief Executive Officer

    26061 Merit Circle, Suite 102

    Laguna Hills, CA 92653

    (949) 766-3636

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copy to:

    Michael Sanders

    Anne G. Peetz

    Reed Smith LLP

    1901 Avenue of Stars, Suite 700

    Los Angeles, CA 90067-6078

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

    Emerging growth company

    ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    EXPLANATORY NOTE

     

    TERMINATION OF REGISTRATION STATEMENTS

    AND

    DEREGISTRATION OF UNSOLD SECURITIES

     

    Sonendo, Inc. (the “Company”) is filing these post-effective amendments (these “Post-Effective Amendments”) to the following Registration Statements on Forms S-8 (the “Registration Statements”), which have been previously filed with the Securities and Exchange Commission (the “SEC”), to deregister any and all of the Company’s securities registered but unsold or otherwise unissued under each such Registration Statement as of the date hereof (note that the number of securities listed as being registered pursuant to each Registration Statement listed below does not take into account corporate actions, such as stock splits, taken in the interim):

     

    •
    Registration Statement No. 333-260680, filed with the SEC on November 2, 2021, registering an original, aggregate of 6,477,589 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), issuable under the Company’s 2007 Stock Plan, 2017 Stock Incentive Plan, 2021 Incentive Award Plan, and 2021 Employee Stock Purchase Plan;

     


     

    •
    Registration Statement No. 333-263803, filed with the SEC on March 23, 2022, registering an additional, aggregate of 1,577,390 shares of Common Stock issuable under the Company’s 2021 Incentive Award Plan and 2021 Employee Stock Purchase Plan;
    •
    Registration Statement No. 333-270367, filed with the SEC on March 8, 2023, registering an additional, aggregate of 2,998,456 shares of Common Stock issuable under the Company’s 2021 Incentive Award Plan and 2021 Employee Stock Purchase Plan;
    •
    Registration Statement No. 333-270368, filed with the SEC on March 8, 2023, registering an original 750,000 shares of Common Stock issuable under the Company’s 2023 Employment Inducement Incentive Award Plan;
    •
    Registration Statement No. 333-277817, filed with the SEC on March 11, 2024, registering an additional, aggregate of 3,812,847 shares of Common Stock issuable under the Company’s 2021 Incentive Award Plan and 2021 Employee Stock Purchase Plan; and
    •
    Registration Statement No. 333-279931, filed with the SEC on June 4, 2024, registering an additional 1,000,000 shares of Common Stock issuable under the Company’s 2023 Employment Inducement Incentive Award Plan.

     

    On April 11, 2024, the New York Stock Exchange LLC (the “NYSE) filed a Form 25 with the SEC to complete the delisting of the Common Stock from the NYSE. The Company thereafter traded on OTC Markets Group Inc.’s (“OTC”) OTCQX U.S. tier (the “OTCQX”). On February 7, 2025, the Company no longer met the continued listing requirements of the OTCQX, and therefore, the Common Stock was moved from the OTCQX to the OTC Pink market. The Company intends to file a Form 15 with the SEC to notify the SEC of its suspended reporting obligation under Section 15(d) of the Securities Exchange Act of 1934 on or about February 26, 2025.

     

    As a result of the delisting and deregistration of the Company’s securities, the Company is terminating all offerings of securities pursuant to the Registration Statements. In accordance with an undertaking made by the Company in the Registration Statements to remove from registration, by means of these Post-Effective Amendments, any securities that had been registered but remain unsold at the termination of the offering, the Company hereby amends the Registration Statements to remove from registration all securities, as applicable, registered under the Registration Statements that remain unsold as of the date of these Post-Effective Amendments.

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Laguna Hills, State of California, on this 26th day of February, 2025.

    Sonendo, Inc.

    By:

    /s/ Bjarne Bergheim

    Name:

    Bjarne Bergheim

    Title:

    President and Chief Executive Officer

    No other person is required to sign these Post-Effective Amendments in reliance upon Rule 478 of the Securities Act of 1933, as amended.

     


    Get the next $SONX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SONX

    DatePrice TargetRatingAnalyst
    3/12/2024Buy → Hold
    Stifel
    1/31/2022$6.90Equal-Weight
    Morgan Stanley
    11/23/2021$16.00Buy
    Stifel
    11/23/2021$15.00Buy
    B of A Securities
    11/23/2021$30.00Buy
    Goldman Sachs
    11/23/2021$17.00Overweight
    Piper Sandler
    More analyst ratings

    $SONX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sonendo Inc.

      SC 13G/A - Sonendo, Inc. (0001407973) (Subject)

      11/14/24 4:40:34 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Sonendo Inc.

      SC 13G - Sonendo, Inc. (0001407973) (Subject)

      11/14/24 1:23:43 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Sonendo Inc. (Amendment)

      SC 13G/A - Sonendo, Inc. (0001407973) (Subject)

      2/14/24 5:15:11 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care

    $SONX
    Leadership Updates

    Live Leadership Updates

    See more
    • Sonendo Strengthens Leadership With Key Strategic Appointments

      John Bostjancic Appointed as Chief Financial Officer Bob Guyatt Appointed as Senior Vice President of Marketing John McGaugh Promoted to Senior Vice President of Operations Sonendo, Inc. (OTCQX:SONX) ("Sonendo"), a leading dental technology company and developer of the GentleWave® System, today announced the appointment of John Bostjancic as Chief Financial Officer, the appointment of Robert Guyatt as Senior Vice President of Marketing, and the promotion of John McGaugh to Senior Vice President of Operations. "Sonendo is embarking on a reset strategy to drive fundamental change within the organization," said Bjarne Bergheim, President and Chief Executive Officer of Sonendo. "We have fil

      6/5/24 4:05:00 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Sonendo Announces New Partnership Agreements with Two Leading Specialty DSOs to Expand Access to the GentleWave® Procedure for Elevated Root Canal Treatment

      The Partnership Agreements Aim to Increase the Number of Endodontic Practices Offering the GentleWave System Sonendo, Inc. (NYSE:SONX), a leading dental technology company and developer of the GentleWave® System, today announced the signing of two new strategic partnership agreements with the country's leading endodontic dental service organizations (DSOs) to expand patient access to a best-in-class root canal experience. As a result of these partnerships, the GentleWave System with CleanFlow™ Technology, which offers a less invasive and less painful alternative to traditional root canal therapy, will be available in more endodontic offices nationwide. Sonendo previously announced the a

      10/4/23 8:00:00 AM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Sonendo, Inc. Announces Inducement Grants Under NYSE Listing Rule 303A.08

      Sonendo, Inc. (NYSE:SONX), a leading dental technology company and developer of the GentleWave® System, today announced that on September 25, 2023, the Compensation Committee of Sonendo's Board of Directors granted restricted stock unit awards covering an aggregate of 14,000 shares of its common stock to two new, non-executive employees to induce them to join the company. The awards were granted under Sonendo's 2023 Employment Inducement Incentive Award Plan (the "Inducement Plan"), which was adopted on March 2, 2023 and provides for the granting of equity awards to prospective employees of Sonendo under NYSE Listing Rule 303A.08. The restricted stock unit awards vest over a four-year p

      9/26/23 8:00:00 AM ET
      $SONX
      Medical/Dental Instruments
      Health Care

    $SONX
    Financials

    Live finance-specific insights

    See more
    • Sonendo, Inc. to Release Third Quarter 2024 Financial Results and Postpone Conference Call on November 12, 2024

      Sonendo, Inc. ("Sonendo") (OTCQX:SONX), a leading dental technology company and developer of the GentleWave® System, today announced that management will postpone the third quarter 2024 conference call that was previously scheduled for after the market close on Tuesday, November 12th, 2024. The Company still intends to file its audited financial results on November 12th, 2024, but has postponed, until further notice, the accompanying conference call. Management will provide commentary on events subsequent to the end of the quarter ending September 30th, 2024, at a later date. About Sonendo Sonendo is a commercial-stage medical technology Company focused on saving teeth from tooth deca

      11/11/24 4:05:00 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Sonendo, Inc. to Report Third Quarter 2024 Financial Results on November 12, 2024

      Sonendo, Inc. ("Sonendo") (OTCQX:SONX), a leading dental technology company and developer of the GentleWave® System, today announced that it will report financial results for the third quarter 2024 after the market close on Tuesday, November 12th, 2024. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results. Investors interested in listening to the conference call may do so by dialing (833) 470-1428 for domestic callers or (404) 975-4839 for international callers, using access code: 788725. Live audio of the webcast will be available at: https://investor.sonendo.com. An archived recording will be available on th

      10/29/24 4:05:00 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Sonendo, Inc. Reports Second Quarter 2024 Financial Results and Raises Full Year Revenue Guidance

      Sonendo, Inc. ("Sonendo" or the "Company") (OTCQX:SONX), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights Generated $8.3 million total revenue for second quarter of 2024 and carried over a healthy console backlog for the second straight quarter; Drove substantial increases in GAAP gross margin and adjusted gross margins (non-GAAP) to 37.5% and 40.7%, respectively, based primarily on lower manufacturing and console warranty costs; Significantly reduced GAAP operating loss to $6.7 million and adjusted EBITDA (non-GAAP) loss to $5.7 million, a 61% and 55% improv

      8/7/24 4:05:00 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care

    $SONX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $SONX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $SONX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $SONX
    SEC Filings

    See more
    • Sonendo downgraded by Stifel

      Stifel downgraded Sonendo from Buy to Hold

      3/12/24 7:33:34 AM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Morgan Stanley initiated coverage on Sonendo with a new price target

      Morgan Stanley initiated coverage of Sonendo with a rating of Equal-Weight and set a new price target of $6.90

      1/31/22 7:34:46 AM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Stifel initiated coverage on Sonendo with a new price target

      Stifel initiated coverage of Sonendo with a rating of Buy and set a new price target of $16.00

      11/23/21 7:43:50 AM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Sonendo, Inc. Announces $5.0 Million Private Placement

      Sonendo, Inc. (OTC:SONX) ("Sonendo" or the "Company"), a leading dental technology company and developer of the GentleWave® System, today announced a private placement of common stock, resulting in gross proceeds of $5.0 million (the "Private Placement"). New and existing investors, including certain directors and officers of the Company, participated in the financing. Sonendo intends to use the proceeds from the financing to expand commercial programs to drive revenue growth, continue executing ongoing business restructuring activities to further reduce operating expenses and accelerate the path to positive adjusted EBITDA and operating cash flow, to retain senior leadership and key emplo

      5/1/25 6:00:00 AM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Sonendo Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

      Sonendo, Inc. (OTC:SONX) ("Sonendo" or the "Company"), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the quarter and year ended December 31, 2024. Quarterly Highlights Generated $8.3 million total revenue for the fourth quarter 2024; Drove substantial 1,570 and 1,260 basis points of GAAP and adjusted (non-GAAP) gross margin expansion for the fourth quarter 2024 to 41.1% and 41.3%, respectively, as compared to the prior year quarter; Significantly reduced GAAP operating loss to $5.6 million and adjusted EBITDA (non-GAAP) loss to $4.7 million for the fourth quarter 2024, an improvement of 45.2% and 45.0%, respectively,

      3/26/25 4:05:00 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Sonendo, Inc. Reports Third Quarter 2024 Financial Results

      Sonendo, Inc. ("Sonendo" or the "Company") (OTCQX:SONX), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Generated $8.0 million total revenue for the third quarter of 2024 and carried over a double-digit console backlog for the third straight quarter; Drove substantial increases in GAAP gross margin and adjusted gross margins (non-GAAP) to 41.2% and 42.6%, respectively, based primarily on lower manufacturing and console warranty costs; Significantly reduced GAAP operating loss to $7.5 million and adjusted EBITDA (non-GAAP) loss to $5.1 million, a 57% and

      11/12/24 4:05:00 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Sr. VP Operations Mcgaugh John P. was granted 500,000 shares, increasing direct ownership by 142% to 852,896 units (SEC Form 4)

      4 - Sonendo, Inc. (0001407973) (Issuer)

      9/19/24 5:48:44 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Bostjancic John J. was granted 600,000 shares, increasing direct ownership by 83% to 1,320,000 units (SEC Form 4)

      4 - Sonendo, Inc. (0001407973) (Issuer)

      9/19/24 5:46:24 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • President and CEO Bergheim Bjarne was granted 1,600,000 shares, increasing direct ownership by 85% to 3,488,518 units (SEC Form 4)

      4 - Sonendo, Inc. (0001407973) (Issuer)

      9/19/24 5:42:53 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • SEC Form D filed by Sonendo Inc.

      D - Sonendo, Inc. (0001407973) (Filer)

      5/12/25 1:21:37 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-K filed by Sonendo Inc.

      10-K - Sonendo, Inc. (0001407973) (Filer)

      3/26/25 4:06:45 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Sonendo Inc.

      EFFECT - Sonendo, Inc. (0001407973) (Filer)

      2/28/25 12:15:03 AM ET
      $SONX
      Medical/Dental Instruments
      Health Care

    $SONX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mcgaugh John P. bought $11,545 worth of shares (116,500 units at $0.10), increasing direct ownership by 47% to 363,797 units (SEC Form 4)

      4 - Sonendo, Inc. (0001407973) (Issuer)

      5/23/24 6:05:19 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Bergheim Olav bought $49,504 worth of shares (520,000 units at $0.10) (SEC Form 4)

      4 - Sonendo, Inc. (0001407973) (Issuer)

      5/17/24 2:30:11 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Pudipeddi Vamsi Mohan Raj bought $47,000 worth of shares (500,000 units at $0.09), increasing direct ownership by 27% to 2,374,498 units (SEC Form 4)

      4 - Sonendo, Inc. (0001407973) (Issuer)

      5/14/24 5:18:33 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care